Which has preferable earnings & valuation, IMNM or NUVL?

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 364.23 -$212.39M -$2.38 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is IMNM or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Nuvalent N/A -40.11% -35.43%

Is PRAX or IMNM more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Immunome N/A -51.15% -47.32%

Is SYRE or IMNM more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Immunome N/A -51.15% -47.32%

Immunome (IMNM) Competitors

$22.32 +0.12 (+0.54%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$22.22 -0.09 (-0.43%)

As of 07/17/2026 07:59 PM Eastern

Compare

IMNM vs. NUVL, KYMR, PRAX, CRNX, and SYRE

Should you buy Immunome stock or one of its competitors? MarketBeat compares Immunome with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunome include Nuvalent (NUVL), Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Immunome compare to Nuvalent?

Immunome (NASDAQ:IMNM) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Nuvalent's return on equity of -40.11% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Nuvalent	N/A	-40.11%	-35.43%

44.6% of Immunome shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immunome has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	364.23	-$212.39M	-$2.38	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Immunome has a beta of 2.07, meaning that its share price is 107% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Immunome presently has a consensus price target of $33.17, suggesting a potential upside of 48.60%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.04%. Given Immunome's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunome is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

In the previous week, Nuvalent had 7 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Nuvalent and 0 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Nuvalent's score of -0.01 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Positive
Nuvalent	Neutral

Summary

Immunome beats Nuvalent on 10 of the 14 factors compared between the two stocks.

How does Immunome compare to Kymera Therapeutics?

Immunome (NASDAQ:IMNM) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Kymera Therapeutics had 7 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Kymera Therapeutics and 0 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Kymera Therapeutics' score of 0.29 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Positive
Kymera Therapeutics	Neutral

Immunome has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	364.23	-$212.39M	-$2.38	N/A
Kymera Therapeutics	$39.21M	242.88	-$311.35M	-$3.57	N/A

Immunome has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Immunome currently has a consensus price target of $33.17, indicating a potential upside of 48.60%. Kymera Therapeutics has a consensus price target of $122.64, indicating a potential upside of 5.93%. Given Immunome's higher possible upside, equities research analysts clearly believe Immunome is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86

Immunome has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunome beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immunome compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Praxis Precision Medicines currently has a consensus target price of $563.50, suggesting a potential upside of 79.22%. Immunome has a consensus target price of $33.17, suggesting a potential upside of 48.60%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 4 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 0 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Praxis Precision Medicines' score of 0.59 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Praxis Precision Medicines	Positive
Immunome	Positive

Praxis Precision Medicines' return on equity of -43.02% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Immunome	N/A	-51.15%	-47.32%

Praxis Precision Medicines has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, Immunome has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market.

Immunome has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,025.23	-$303.27M	-$13.37	N/A
Immunome	$6.94M	364.23	-$212.39M	-$2.38	N/A

Summary

Praxis Precision Medicines beats Immunome on 11 of the 16 factors compared between the two stocks.

How does Immunome compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Immunome. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 0 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Crinetics Pharmaceuticals' score of 0.32 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Neutral
Immunome	Positive

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Crinetics Pharmaceuticals currently has a consensus target price of $78.27, suggesting a potential downside of 6.66%. Immunome has a consensus target price of $33.17, suggesting a potential upside of 48.60%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Immunome has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Immunome	N/A	-51.15%	-47.32%

Immunome has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,148.34	-$465.32M	-$5.13	N/A
Immunome	$6.94M	364.23	-$212.39M	-$2.38	N/A

Summary

Immunome beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Immunome compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Immunome (NASDAQ:IMNM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Immunome. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,903.62	-$155.20M	-$2.08	N/A
Immunome	$6.94M	364.23	-$212.39M	-$2.38	N/A

Spyre Therapeutics' return on equity of -42.88% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Immunome	N/A	-51.15%	-47.32%

Spyre Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market. Comparatively, Immunome has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

Spyre Therapeutics presently has a consensus price target of $101.42, suggesting a potential upside of 1.18%. Immunome has a consensus price target of $33.17, suggesting a potential upside of 48.60%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Spyre Therapeutics had 6 more articles in the media than Immunome. MarketBeat recorded 6 mentions for Spyre Therapeutics and 0 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Spyre Therapeutics' score of 0.62 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyre Therapeutics	Positive
Immunome	Positive

Summary

Spyre Therapeutics beats Immunome on 11 of the 16 factors compared between the two stocks.

Get Immunome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNM vs. The Competition

Export

Metric	Immunome	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.53B	$3.69B	$7.01B	$12.29B
Dividend Yield	N/A	2.17%	2.67%	9.35%
P/E Ratio	-9.38	21.21	27.28	23.90
Price / Sales	364.23	304.50	527.76	91.71
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	3.88	8.28	10.70	6.18
Net Income	-$212.39M	$23.81M	$3.59B	$332.02M
7 Day Performance	-4.41%	-3.47%	-2.20%	-2.05%
1 Month Performance	19.10%	2.69%	1.63%	-2.18%
1 Year Performance	110.96%	45.93%	25.64%	17.67%

Immunome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNM Immunome	3.4075 of 5 stars	$22.32 +0.5%	$33.17 +48.6%	+111.0%	$2.53B	$6.94M	N/A	40	Positive News Gap Down
NUVL Nuvalent	2.0042 of 5 stars	$123.97 +0.0%	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40	News Coverage Analyst Upgrade
KYMR Kymera Therapeutics	1.4632 of 5 stars	$111.13 +0.7%	$121.73 +9.5%	+150.7%	$9.19B	$39.21M	N/A	170	Analyst Forecast
PRAX Praxis Precision Medicines	3.2517 of 5 stars	$317.00 +0.8%	$563.50 +77.8%	+483.9%	$8.87B	$8.55M	N/A	110	Gap Down
CRNX Crinetics Pharmaceuticals	1.334 of 5 stars	$83.67 +0.0%	$78.27 -6.5%	+169.6%	$8.82B	$7.70M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNM) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Competitors

IMNM vs. NUVL, KYMR, PRAX, CRNX, and SYRE

How does Immunome compare to Nuvalent?

Summary

How does Immunome compare to Kymera Therapeutics?

Summary

How does Immunome compare to Praxis Precision Medicines?

Summary

How does Immunome compare to Crinetics Pharmaceuticals?

Summary

How does Immunome compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunome (IMNM) Competitors

IMNM vs. NUVL, KYMR, PRAX, CRNX, and SYRE

How does Immunome compare to Nuvalent?

Is IMNM or NUVL more profitable?

Do insiders & institutionals have more ownership in IMNM or NUVL?

Which has preferable earnings & valuation, IMNM or NUVL?

Which has more volatility & risk, IMNM or NUVL?

Do analysts rate IMNM or NUVL?

Does the media favor IMNM or NUVL?

Summary

How does Immunome compare to Kymera Therapeutics?

Does the media favor IMNM or KYMR?

Which has better valuation and earnings, IMNM or KYMR?

Is IMNM or KYMR more profitable?

Do analysts prefer IMNM or KYMR?

Which has more risk and volatility, IMNM or KYMR?

Do institutionals & insiders have more ownership in IMNM or KYMR?

Summary

How does Immunome compare to Praxis Precision Medicines?

Do analysts recommend PRAX or IMNM?

Do insiders & institutionals have more ownership in PRAX or IMNM?

Does the media refer more to PRAX or IMNM?

Is PRAX or IMNM more profitable?

Which has more risk & volatility, PRAX or IMNM?

Which has better valuation & earnings, PRAX or IMNM?

Summary

How does Immunome compare to Crinetics Pharmaceuticals?

Which has more volatility and risk, CRNX or IMNM?

Does the media prefer CRNX or IMNM?

Do institutionals & insiders have more ownership in CRNX or IMNM?

Do analysts recommend CRNX or IMNM?

Is CRNX or IMNM more profitable?

Which has preferable earnings & valuation, CRNX or IMNM?

Summary

How does Immunome compare to Spyre Therapeutics?

Do institutionals and insiders have more ownership in SYRE or IMNM?

Which has higher valuation & earnings, SYRE or IMNM?

Is SYRE or IMNM more profitable?

Which has more risk & volatility, SYRE or IMNM?

Do analysts prefer SYRE or IMNM?

Does the media refer more to SYRE or IMNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNM vs. The Competition

Immunome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools